Patent Yard Sign in
Canadian application, no grantCanada

Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient

CA 2476406 A1 · Owner: Takahashi, Shinya · Inventors: Takeuchi, Jun; Takahashi, Shinya; Seko, Takuya

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

Fused pyridazine derivatives represented by the following general formula (I) (wherein each symbol is as defined in the description) and pharmaceutically acceptable salts thereof: (I) Because of inhibiting poly(ADPribose)polymerase, the compounds represented by the general formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain cord, heart, digestive tract, skeletal muscle retina, etc.), inflammatory , diseases (inflammatory bowel disease multiple cerebrosclerosis, arthritis, etc.) neurodegenerative diseases (extrapyramidal disorder Alzheimer~s , disease, muscular dystrophy lumbar spinal canal stenosis, etc.), diabetes shock, head trauma, renal …

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed February 18, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 18, 2023.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 18, 2025.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledFebruary 18, 2003
GrantedNo grant recorded
Term endedFebruary 18, 2023
Patent numberCA 2476406 A1
Classification (IPC)C07D237/32 +2 more

Timeline

Timeline From CIPO dates

2004200620082010201220142016201820202022Application filedFeb 18, 2003Term endedFeb 18, 2023

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.